iShares Biotechnology ETF is a ETF series of iShares Trust (series S000004350). Net assets $8.1B as of 2026-03-31. Index fund.
Showing 15 of 200 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| BlackRock Funds III | — | $784.8M | 966.20% |
| Gilead Sciences, Inc. | — | $629.4M | 774.81% |
| Amgen, Inc. | — | $609.8M | 750.75% |
| Vertex Pharmaceuticals, Inc. | — | $604.6M | 744.37% |
| Regeneron Pharmaceuticals, Inc. | — | $585.8M | 721.24% |
| Alnylam Pharmaceuticals, Inc. | — | $324.1M | 399.05% |
| Insmed, Inc. | — | $259.7M | 319.66% |
| Argenx SE | — | $249.7M | 307.36% |
| Biogen, Inc. | — | $200.0M | 246.25% |
| Natera, Inc. | — | $196.1M | 241.44% |
| United Therapeutics Corp. | — | $187.1M | 230.33% |
| BeOne Medicines Ltd. | — | $157.1M | 193.46% |
| Incyte Corp. | — | $138.2M | 170.09% |
| Moderna, Inc. | — | $136.8M | 168.39% |
| Illumina, Inc. | — | $136.5M | 168.03% |
| Report date | Net assets |
|---|---|
| 2026-03-31 | $8.1B |
| 2025-12-31 | $8.3B |
| 2025-09-30 | $5.9B |
| 2025-06-30 | $5.3B |
| 2025-03-31 | $5.8B |
| 2024-12-31 | $6.5B |
| 2024-09-30 | $7.6B |
| 2024-06-30 | $7.4B |